1. Home
  2. FMNB vs GERN Comparison

FMNB vs GERN Comparison

Compare FMNB & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Farmers National Banc Corp.

FMNB

Farmers National Banc Corp.

HOLD

Current Price

$14.39

Market Cap

839.7M

Sector

Finance

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.35

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FMNB
GERN
Founded
1887
1990
Country
United States
United States
Employees
N/A
258
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
839.7M
808.3M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
FMNB
GERN
Price
$14.39
$1.35
Analyst Decision
Hold
Hold
Analyst Count
2
3
Target Price
$15.00
$2.17
AVG Volume (30 Days)
387.0K
12.5M
Earning Date
04-22-2026
05-06-2026
Dividend Yield
4.89%
N/A
EPS Growth
18.85
N/A
EPS
0.36
N/A
Revenue
$279,922,000.00
N/A
Revenue This Year
$52.63
$26.91
Revenue Next Year
$8.28
$43.75
P/E Ratio
$39.58
N/A
Revenue Growth
3.89
N/A
52 Week Low
$12.23
$1.04
52 Week High
$15.50
$2.01

Technical Indicators

Market Signals
Indicator
FMNB
GERN
Relative Strength Index (RSI) 55.73 61.20
Support Level $13.71 $1.22
Resistance Level $14.68 $1.46
Average True Range (ATR) 0.24 0.07
MACD -0.01 0.03
Stochastic Oscillator 72.56 93.10

Price Performance

Historical Comparison
FMNB
GERN

About FMNB Farmers National Banc Corp.

Farmers National Banc Corp is a financial holding company based in the U.S. Along with its subsidiaries, it operates in the domestic banking, trust, retirement consulting, insurance, and financial management industries. The group offers a full range of commercial and retail banking services, including checking accounts, savings accounts, time deposit accounts, commercial, mortgage, and installment loans, safe deposit boxes, ATMs, internet banking, and other banking services. Additionally, it offers personal and corporate trust services in the areas of estate settlement, trust administration, employee benefit plans, and retirement services; insurance products, and other financial products and services. The group's reportable segments are Bank, which generates the maximum revenue, and Trust.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: